[
  {
    "ts": null,
    "headline": "Viatris Inc. stock falls Friday, underperforms market",
    "summary": "Viatris Inc. stock falls Friday, underperforms market",
    "url": "https://finnhub.io/api/news?id=5f134d953ba9d676118c36e4e8bd9c1b76088df0fd37b82d06e0526b84932e2a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751044740,
      "headline": "Viatris Inc. stock falls Friday, underperforms market",
      "id": 135612974,
      "image": "",
      "related": "VTRS",
      "source": "MarketWatch",
      "summary": "Viatris Inc. stock falls Friday, underperforms market",
      "url": "https://finnhub.io/api/news?id=5f134d953ba9d676118c36e4e8bd9c1b76088df0fd37b82d06e0526b84932e2a"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call",
    "summary": "Viatris' first quarter results for 2025 were met with a positive market response, largely due to strong execution in its global branded portfolio and pipeline advancements, despite revenue coming in below consensus. Management highlighted robust growth in Europe and China, as well as progress in its portfolio of innovative medicines. CEO Scott Smith noted, “We were particularly pleased with our strong execution and growth in Europe and China this quarter,” attributing operational revenue decline",
    "url": "https://finnhub.io/api/news?id=d0907f77c4a9a765a5fdca1786a7d593271fa909e4bf9327381b57856350817b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751026012,
      "headline": "The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call",
      "id": 135603232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris' first quarter results for 2025 were met with a positive market response, largely due to strong execution in its global branded portfolio and pipeline advancements, despite revenue coming in below consensus. Management highlighted robust growth in Europe and China, as well as progress in its portfolio of innovative medicines. CEO Scott Smith noted, “We were particularly pleased with our strong execution and growth in Europe and China this quarter,” attributing operational revenue decline",
      "url": "https://finnhub.io/api/news?id=d0907f77c4a9a765a5fdca1786a7d593271fa909e4bf9327381b57856350817b"
    }
  },
  {
    "ts": null,
    "headline": "Viatris gains China approval for Yupelri to treat COPD",
    "summary": "Viatris will handle all development and commercialisation aspects of Yupelri in the Chinese market.",
    "url": "https://finnhub.io/api/news?id=555cecd466d4e3adc657f0d43f4d2a7b0e2bc7897651d8317a26c6735e20b194",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751024193,
      "headline": "Viatris gains China approval for Yupelri to treat COPD",
      "id": 135596858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris will handle all development and commercialisation aspects of Yupelri in the Chinese market.",
      "url": "https://finnhub.io/api/news?id=555cecd466d4e3adc657f0d43f4d2a7b0e2bc7897651d8317a26c6735e20b194"
    }
  },
  {
    "ts": null,
    "headline": "Viatris’ presbyopia drug clears second Phase III trial",
    "summary": "There are only two therapies approved for presbyopia in the US.",
    "url": "https://finnhub.io/api/news?id=6ffe6ccbdd339482a0062e06b32e8be0bc24d2d40bffc99107869f1ca18bf393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751016294,
      "headline": "Viatris’ presbyopia drug clears second Phase III trial",
      "id": 135596859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "There are only two therapies approved for presbyopia in the US.",
      "url": "https://finnhub.io/api/news?id=6ffe6ccbdd339482a0062e06b32e8be0bc24d2d40bffc99107869f1ca18bf393"
    }
  }
]